CD34 and acute myeloid leukemia: Finally, to validate that STC1 could mimic the effect of AML on HSPCs in vivo, we implanted NSG-S mice with scaffolds containing MSCs with CD34+ cells and subcutaneously injected rSTC1 every other day (Figure 5A).